AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pleural Fluid Analysis
Description: Cytomorphology Cytochemistry Adenosine Deaminase Value
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pleural Fluid Analysis
Description: Cytomorphology Cytochemistry Adenosine Deaminase Value
Study NCT01611064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
Study NCT01611064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air
Description: Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
Study NCT04139044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training for Stable Ankle
Description: Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
Study NCT04139044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training for Unstable Ankle
Description: Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
Study NCT02410655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
Study NCT02410655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
Study NCT03339869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
Study NCT03122275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized text message invitation ( Step 1a)
Description: Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
Study NCT03122275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized automatic phone call invitation (Step 1b)
Description: Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
Study NCT03122275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secretary phone call (Step 2)
Description: Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
Study NCT03122275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health professional face-to-face appointment (Step 3)
Description: Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening.
Study NCT03122275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Letter
Description: A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm.
Study NCT02777697 — intervention group
Intervention type: OTHER
Intervention: chronic pain
Study NCT04494230 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
Study NCT01406288 — intervention group
Intervention type: OTHER
Intervention: HUS standard coverage care (including in ICU)
Description: HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
Study NCT01088464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
Study NCT01088464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 800 mg intravenously, every 2 weeks
Study NCT01088464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 800 mg intravenously, Days 1 and 8 every 3 weeks
Study NCT01974089 — intervention group
Intervention type: OTHER
Intervention: Dysphagia
Description: Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
Study NCT01611948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 125mg/day for 8 weeks
Study NCT01611948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125mg/d placebo pill for 8 weeks
Study NCT01611948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study NCT01611948 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study NCT01460095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HbA1c measurement and education
Description: three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
Study NCT00749879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
Study NCT03985475 — intervention group
Intervention type: OTHER
Intervention: skin sample
Description: For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
Study NCT04807699 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
Study NCT01128361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
Study NCT01128361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
Study NCT01121523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue directed tactile stimulation
Description: Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
Study NCT01121523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue directed tactile stimulation
Description: Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
Study NCT04085341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-102
Description: Intravitreal injection of GB-102
Study NCT01891097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours.
Study NCT01891097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT02393677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.5% 30 ml was used to block brachial plexus
Study NCT02393677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine with Dexmedetomidine
Description: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
Study NCT04249323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176 Lipid Capsule Formulation
Description: CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
Study NCT04249323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176 Lipid Capsule Formulation
Description: Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
Study NCT04249323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
Study NCT02338011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
Study NCT02338011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
Study NCT02293850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
Study NCT01117454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flecainide Acetate
Description: oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
Study NCT01117454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, similar in appearance to flecainide
Study NCT01117454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
Study NCT03343392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetam/ketoro tromet group
Description: One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
Study NCT03343392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
Study NCT00794495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days
Study NCT00794495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study NCT00375557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex ER
Description: Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
Study NCT00375557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
Study NCT03915808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid group
Description: supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
Study NCT03915808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil group
Description: supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
Study NCT04169087 — intervention group
Intervention type: OTHER
Intervention: QoR-15
Description: The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
Study NCT02960178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based training
Description: Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
Study NCT02960178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking training
Description: Over-ground practice of stepping and balance tasks in standing. One hour in duration.
Study NCT01671020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
Study NCT01671020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
Study NCT02053909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02053909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study NCT04115579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit 1 Control
Description: Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
Study NCT04115579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit 2 Test
Description: Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
Study NCT00558155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peptisorb
Description: standard isocaloric eteral diet (1 ml = 1 kcal)
Study NCT00558155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stresson
Description: Oligopeptic, enteral diet (1 ml=1.25 kcal)
Study NCT00558155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Study NCT00558155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven, Dipeptiven
Description: Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Study NCT01587378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Study NCT01587378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Study NCT02616757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight Omnisense Quantitative Ultrasound
Description: Ultrasound
Study NCT02616757 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sunlight Omnisense Quantitative Ultrasound
Description: Ultrasound
Study NCT03029741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0284
Description: Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
Study NCT03029741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD0284
Description: Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
Study NCT03426293 — intervention group
Intervention type: OTHER
Intervention: Measuring the ACT to determine effect of heparin
Description: Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
Study NCT02248948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
Study NCT02248948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides
Description: Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
Study NCT01468220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Endurance training three times per week over six weeks
Study NCT01468220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance training
Description: Endurance training three times per week over six weeks
Study NCT00283049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin glargine administered subcutaneously once daily.
Study NCT00283049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)